
Pharma R&D Spending 2026: R&D as % of Revenue, Top 25 Drugmakers
A 2026 analyst report ranking the top 25 drugmakers by R&D spending and R&D intensity, with PhRMA, Deloitte, and IQVIA benchmarks, five case studies, and AI's impact on pharma R&D.
IntuitionLabs is now a member of the Claude Partner Network – AI training and upskilling with Claude for pharma and biotech. Book a call.

A 2026 analyst report ranking the top 25 drugmakers by R&D spending and R&D intensity, with PhRMA, Deloitte, and IQVIA benchmarks, five case studies, and AI's impact on pharma R&D.

A 2026 analyst report on the cost to bring a drug to market, comparing Tufts CSDD's $2.6 billion figure, Deloitte's $2.671 billion 2025 estimate, and lower academic estimates, with phase-by-phase trial costs and 5 case studies.
© 2026 IntuitionLabs. All rights reserved.